Key extracted elements included, study title, condition, intervention, primary outcome measures locations and enrolment as shown in Table 2
Eli Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist. It is not available for public use and is being studied in Phase 3 clinical trials for obesity, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea (OSA), chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD)
However, tirzepatide differs from the other medications in that it is a dual-action GLP-1 (short for glucagon-like peptide 1) and GIP (short for glucose-dependent insulinotropic polypeptide) medication
The peptide chains unfold and aggregate, rendering the medication less effective at binding to GLP-1 receptors and triggering the appetite-suppressing cascade your body relies on for weight management
Concurrent dosing reduces efficacy by creating NAD+ demand spikes and competitive receptor saturationtiming separation is the critical variable for synergy
